SAN DIEGO, Oct. 25 – Ciphergen Biosystems on Thursday posted third-quarter revenues of $5.4 million compared to $2.3 million for the same quarter a year ago, the company announced.

“This was a very strong quarter for Ciphergen, as our revenue growth accelerated and met plan,” William Rich, CEO of Ciphergen, said in a statement. “We believe that investment in our sales force and new product offerings are paying off, as well as the delivery of collaboration revenues through our Biomarker Centers.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.